Hydroxychloroquine Use, Preeclampsia, and Preterm Delivery Complications in Systemic Lupus Erythematosus Pregnancies: Is There a Protective Effect?
Arthritis Care & Research · 2026
DOI: 10.1002/acr.80046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, 2026. Verfasst von Sadaf Sediqi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology and Population Health, Stanford University, Stanford, California. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Hydroxychloroquine, Pre-Eclampsia, Premature Birth. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Objective
Systemic lupus erythematosus (SLE) increases the risk of adverse pregnancy outcomes, including preeclampsia and preterm delivery. Hydroxychloroquine (HCQ), widely used to manage SLE, has shown mixed associations with pregnancy outcomes. We investigated the association between HCQ use and risks of preeclampsia/eclampsia and preterm delivery, accounting for maternal covariates in a population‐based cohort of SLE pregnancies.
Methods
We studied 847 singleton pregnancies among 597 publicly insured women with SLE in the British Columbia Perinatal Data Registry (mean ± SD maternal age 33.1 ± 4.6 years; 43% nulliparous). SLE was identified before pregnancy, and HCQ exposure during pregnancy was defined using multiple approaches, including ≥2 fills or ≥60 days’ supply during the 20 weeks of pregnancy. Modified Poisson regression estimated risk ratios (RRs) and 95% confidence intervals (CIs) using propensity scores to address confounding. Stratified analyses examined effect modification. For preterm delivery, we conducted a time‐to‐event analysis using a Cox proportional hazards model. Multiple sensitivity analyses explored definitions of SLE, HCQ exposures, and outcomes.
Results
Pregnancies with ≥2 fills or ≥60 days’ supply compared to no fills had an adjusted RR of 0.92 (95% CI 0.47–1.80). Results were similar when expanding the exposure window to include three months preconception. We found no association across different definitions for preterm delivery. The stratified analyses results showed no appreciable differences.
Conclusion
Early pregnancy HCQ use in patients with SLE was not significantly associated with reduced risk of preeclampsia or preterm delivery. Further studies with larger cohorts are needed to clarify these associations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Epidemiology and Population Health, Stanford University, Stanford, California.
- Arthritis Research Canada, Vancouver, British Columbia, Canada.
- Division of Rheumatology, University of British Columbia, Vancouver, British Columbia, Canada.
- Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, California.
ORCID-Profile: Antonio Avina-Zubieta, Julia F Simard
Förderung
- NIAMS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Sediqi, S., Lu, N., Avina-Zubieta, A., & Simard, J. F. (2026). Hydroxychloroquine Use, Preeclampsia, and Preterm Delivery Complications in Systemic Lupus Erythematosus Pregnancies: Is There a Protective Effect?. Arthritis Care & Research. https://doi.org/10.1002/acr.80046
Vancouver
Sediqi S, Lu N, Avina-Zubieta A, Simard JF. Hydroxychloroquine Use, Preeclampsia, and Preterm Delivery Complications in Systemic Lupus Erythematosus Pregnancies: Is There a Protective Effect?. Arthritis Care & Research. 2026. doi:10.1002/acr.80046
BibTeX
@article{Sediqi2026,
author = {Sediqi, Sadaf and Lu, Na and Avina-Zubieta, Antonio and Simard, Julia F},
title = {Hydroxychloroquine Use, Preeclampsia, and Preterm Delivery Complications in Systemic Lupus Erythematosus Pregnancies: Is There a Protective Effect?},
journal = {Arthritis Care & Research},
year = {2026},
doi = {10.1002/acr.80046}
}
EUVIMED